The Ulitas 5mg Tablet is used in the treatment of the following:

• Uterine fibroids
• Emergency Contraceptive

Ulitas 5mg Tablet, as a selective progesterone receptor modulator (SPRM), is prescribed to help manage the symptoms associated with uterine fibroids by reducing their size and alleviating related discomfort. It works by targeting the progesterone receptors in the body, which are involved in the growth of fibroids and the regulation of menstruation. This medication helps to control menstrual bleeding and decrease the size of fibroids, thus improving the quality of life for women with symptomatic uterine fibroids.

Inform your healthcare provider about all your medicines, including prescription, over-the-counter, nutritional or vitamin supplements, and herbal products. Certain medications may interact with Ulitas 5mg Tablet and reduce effectiveness by causing undesirable side effects. 

• Store Ulitas 5mg Tablet in a refrigerator between 20°C to 25°C (68°F to 77°F).
• Keep away from moisture, heat, and light.
• It should not be frozen.
• Keep it in its original packaging until it is ready to be used.
• Keep out of the reach of children and pets.

Ulitas 5mg Tablet is typically used as a single oral dose for emergency contraception within 120 hours (5 days) of unprotected sexual intercourse. For uterine fibroid treatment, it's usually taken as one tablet daily with or without food for a specified treatment period. To ensure effectiveness, follow your healthcare provider's instructions precisely. If using for emergency contraception, take it immediately after unprotected sex. If taking for fibroids, adhere to the prescribed schedule and consult your doctor for guidance on any missed doses or concerns.

Like all medications, Ulipristal acetates cause some side effects, although not everyone will experience them. 

Serious side effects of Ulitas 5mg Tablet are:

• Severe abdominal pain
• Allergic reactions
• Liver problems (yellowing of the skin or eyes, dark urine, nausea, vomiting, loss of appetite, abdominal pain)

Common side effects of Ulitas 5mg Tablet are:

• Headache
• Nausea
• Abdominal pain or discomfort
• Menstrual changes (heavier or lighter bleeding, changes in cycle)
• Fatigue
• Dizziness

Ulitas 5mg Tablet should be approached carefully. Caution is advised for individuals with liver impairments, as the medication is metabolised by the liver. Allergic reactions are possible, necessitating prompt medical attention if symptoms like rash, swelling, or difficulty breathing occur. The impact on menstrual cycles requires monitring, and any significant changes or irregular bleeding patterns should be discussed with a healthcare provider. 

Ulitas 5mg Tablet is not recommended during pregnancy or while breastfeeding due to potential risks. Patients should inform their healthcare providers about their medications to avoid interactions. This medication can interact with certain medications, potentially affecting their effectiveness or causing adverse effects. 

Drugs that are strong CYP3A4 inducers or inhibitors, such as rifampicin and ketoconazole, can alter its metabolism, while hormonal contraceptives may be less effective if taken concurrently. Additionally, repeated use within a single menstrual cycle and its use in individuals under 18 should be carefully considered. Adherence to prescribed dosages, follow-up appointments, and seeking medical attention for any concerning symptoms is strongly advised.

1. Allergan Inc., [Revised on 3rd Jul 2019] [Accessed on 26th Aug 2023], https://allergan-web-cdn-prod.azureedge.net/allergancanadaspecialty/allergancanadaspecialty/media/actavis-canada-specialty/en/products/pms/2019-07-03-fibristal-pm-english.pdf
2. Gedeon Richter Plc., Electronic Medicines Compendium (EMC), [Revised on Jan 2021] [Accessed on 26th Aug 2023], https://www.medicines.org.uk/emc/files/pil.3951.pdf
3. Paweł Milart et al., Ulipristal acetate as a treatment option for uterine fibroids, Menopause Rev, 2017; 16(4): 133-136, https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5824685/pdf/MR-16-31511.pdf
4. Ellis R. Levin, Wendy S. Vitek, and Stephen R. Hammes, Estrogens, Progestins, and the Female Reproductive Tract, Goodman & Gilman’s: The Pharmacological Basis of Therapeutics, 13th Edition, 2018, 803-831.
5. Watson Pharma, Inc, Food and Drug Safety Administration (FDA) [Revised on August 2008] [Accessed on 26th Aug 2023], https://www.accessdata.fda.gov/drugsatfda_docs/label/2010/022474s000lbl.pdf